Thiogenesis Therapeutics' MELAS Abstract Accepted for Late-Breaking News Presentation at Mitocon 2026

Executive Summary

• Thiogenesis Therapeutics announced that an abstract summarizing preliminary Phase 2 MELAS trial data for TTI‑0102 has been accepted as a Late‑Breaking News poster at the Mitocon Conference 2026 in Pisa.
• The poster will present early pharmacokinetic and pharmacodynamic results, reinforcing proof‑of‑concept and supporting continued development of TTI‑0102 in MELAS and upcoming trials in Leigh syndrome spectrum.
• CEO Patrice Rioux highlighted the significance of the late‑breaking selection as evidence of the scientific importance of the data generated to date.

Key Details

• Abstract Acceptance: Title – “Pharmacokinetics and Pharmacodynamics of TTI‑0102 in MELAS”; selected for Late‑Breaking News poster session, to be presented on January 23, 2026 at Mitocon Conference 2026 (Pisa, Italy).
• Phase 2 MELAS Trial: Randomized, double‑blind, placebo‑controlled, multi‑center study evaluating safety, tolerability, PK, PD, and exploratory efficacy of oral TTI‑0102 in patients with mitochondrial encephalopathy, lactic acidosis, and stroke‑like episodes.
• Interim Findings (previously disclosed): Demonstrated biological proof‑of‑concept and biomarker activity consistent with TTI‑0102’s mechanism of action.
• CEO Quote: “Being selected for a late‑breaking presentation at Mitocon underscores the scientific importance of the data generated in our Phase 2 MELAS study… supports continued clinical development in MELAS and related mitochondrial disorders, including our upcoming Phase 2a trial in Leigh syndrome spectrum in the U.S.” – Patrice Rioux, MD, Ph.D., CEO & Co‑Founder.
• Future Plans: Ongoing Phase 2a IND‑cleared trial planned for Leigh syndrome spectrum (U.S.) and additional programs in pediatric MASH and nephropathic cystinosis.

Notable Quotes

“The pharmacokinetic and pharmacodynamic profile observed to date is consistent with TTI‑0102's proposed mechanism of action and supports continued clinical development in MELAS and related mitochondrial disorders.” – Patrice Rioux, MD, Ph.D., CEO & Co‑Founder.